Clinical Trials Logo

Liver Transplantation clinical trials

View clinical trials related to Liver Transplantation.

Filter by:

NCT ID: NCT00778687 Completed - Clinical trials for Liver Transplantation

Heart Rate Variability Change After Liver Transplantation

Start date: October 2008
Phase: N/A
Study type: Observational

Cirrhotic cardiomyopathy describes a hyperdynamic state with the presentation of high cardiac output and low systemic vascular resistance. And the latent heart failure becomes obvious under physiologic and pharmacologic stress. The goal of our study is to assess the effects of liver transplantation on the heart rate variability in patients with end stage liver disease.

NCT ID: NCT00722332 Completed - Hepatitis B Clinical Trials

Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Start date: February 2008
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess the pharmacokinetics, safety and efficacy of HepaGam B in combination with antiviral therapy for the prevention of hepatitis B virus (HBV) recurrence following HBV-related orthotopic liver transplant.

NCT ID: NCT00720408 Completed - Clinical trials for Liver Transplantation

A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.

Start date: December 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF and steroid withdrawal in de novo Liver transplant recipients

NCT ID: NCT00719745 Completed - Clinical trials for Liver Transplantation

A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients

Start date: February 2006
Phase: Phase 3
Study type: Interventional

To evaluate and to compare efficacy and safety of MR4 versus Prograf in patients undergoing primary liver transplantation.

NCT ID: NCT00718575 Terminated - Clinical trials for Liver Transplantation

The Effects of Glucose/Ischemic Preconditioning on Reperfusion Injury in Deceased-Donor Liver Transplantation

Start date: August 2008
Phase: Phase 3
Study type: Interventional

Standard liver retrieval procedures for transplantation from a deceased donor inevitably result in a "reperfusion injury" to the liver tissue. The purpose of this research study is to find out whether treatment of the liver with a "preconditioning" protocol before its removal from the donor will help reduce any of this injury. The "preconditioning" treatment being tested has two components. Firstly, a solution of glucose+insulin is infused and secondly, blood flow to the liver is stopped briefly (10 minutes) and then resumed. Both strategies, individually, have been shown to reduce liver tissue injury in human studies. We hypothesize that combining both strategies will have a clinical benefit to patients and will improve liver function following transplant.

NCT ID: NCT00717314 Completed - Clinical trials for Liver Transplantation

A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.

Start date: May 2008
Phase: Phase 4
Study type: Interventional

This 2 arm study will compare the efficacy and safety of switching to CellCept combined with different regimens of reduced calcineurin inhibitors (CNI) in patients with liver transplants. Patients currently receiving CNI treatment will be randomized into one of 2 groups to receive either 1) CellCept 2.0g/day po bid + 50% reduction of CNI from baseline or 2) CellCept 2.0g/day po bid + >=75% reduction of CNI from baseline. The anticipated time on study treatment is 1 year, and the target sample size is <100 individuals.

NCT ID: NCT00701272 Enrolling by invitation - Hepatitis C Clinical Trials

FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation

Start date: June 2008
Phase: N/A
Study type: Observational

The main objective of this study is to assess whether a recently-developed bioassay for the molecule "secreted fibrinogen-like protein 2" (sFGL2) can be used to predict the recurrence and/or progression of Hepatitis C Virus disease in post liver transplant patients. The hypothesis is that patients with chronic HCV have higher than normal levels of sFGL2 in their blood both pre- and post-transplantation and that this will inhibit their ability to clear HCV, and influence the progression of HCV disease when it recurs.

NCT ID: NCT00698399 Completed - Liver Transplant Clinical Trials

Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients

Start date: March 2008
Phase: N/A
Study type: Observational

This is an observational study examining serum markers in patients who are undergoing either a cadaveric liver transplant or a living related liver transplant.

NCT ID: NCT00693524 Completed - Clinical trials for Liver Transplantation

Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX

TAST
Start date: November 2002
Phase: Phase 2
Study type: Interventional

Study to evaluate the benefits and any risks of the delayed administration of tacrolimus in a combined regimen of mycophenolate mofetil and monoclonal anti-IL2R antibodies (daclizumab), in comparison with a standard steroid + tacrolimus double drug regimen

NCT ID: NCT00682110 Completed - Clinical trials for Liver Transplantation

Hemodynamic Measurements During Liver Transplantation

OLT
Start date: July 2007
Phase: N/A
Study type: Observational

The purpose of the study is to determine if the less invasive monitors are as reliable for measuring heart function in patients undergoing liver transplantation as the more invasive pulmonary artery.